Taken together, these data suggest the relevance of targeting S6K2 in cholangiocarcinoma, bladder, endometrial, esophagogastric, ovarian, head, and neck, and to a lesser extent in breast cancer. This evidence concerns the gene RPS6KB2 and cholangiocarcinoma.